Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease

JAMA

Volumn 279, Issue 24, 1998, Pages 1955-1961

  Lamarche, Benoît ^a   Tchernof, André ^a   Mauriège, Pascale ^a   Cantin, Bernard ^a   Dagenais, Gilles R ^b   Lupien, Paul J ^a   Després, Jean Pierre ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DIET RESTRICTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PARTICLE SIZE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0032562946     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.24.1955     Document Type: Article

References (45)

1. Castelli WP. Epidemiology of coronary heart disease: the Framingham Study. Am J Med. 1984;76: 4-12.
2. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256:2823-2828.
3. Genest JJ, McNamara JR, Ordovas JM, et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormality in men with premature coronary heart disease. J Am Coll Cardiol. 1992;19: 792-802.
4. Ginsburg GS, Safran C, Pasternak RC. Frequency of low serum high-density lipoprotein cholesterol levels in hospitalized patients with desirable total cholesterol levels. Am J Cardiol. 1991;68: 187-192.
5. Superko HR. Beyond LDL cholesterol reduction. Circulation. 1996;94:2351-2354.
6. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb Vasc Biol. 1991; 11:2-14.
7. Lamarche B, Després JP, Moorjani S, Cantin B, Dagenais GR, Lupien PJ. Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease: results from the Québec Cardiovascular Study. Atherosclerosis. 1996;119:235-245.
8. Manninen V, Tenkanen L, Koshinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation. 1992;85:37-45.
9. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease: the PROCAM experience. Am J Cardiol. 1992;70:733-737.
10. Assmann G, Schulte H. Identification of individuals at high risk for myocardial infarction. Atherosclerosis. 1994;110(suppl):S11-S21.
11. Després JP, Lamarche B, Mauriège P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334: 952-957.
12. Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec Cardiovascular Study. Circulation. 1996;94:273-278.
13. Lamarche B, Després JP, Moorjani S, Cantin B, Dagenais GR, Lupien PJ. Prevalence of dyslipidemic phenotypes in ischemic heart disease: prospective results from the Québec Cardiovascular Study. Am J Cardiol. 1995;75:1189-1195.
14. Lamarche B, Tchernof A, Dagenais GR, Cantin B, Lupien PJ, Després JP. Small, dense LDL particles and the risk of ischemic heart disease: prospective results from the Québec Cardiovascular Study. Circulation. 1997;95:69-75.
15. Lamarche B, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Després JP. Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men: prospective results from the Québec Cardiovascular Study. Arterioscler Thromb Vasc Biol. 1997;17:1098-1105.
16. Dagenais GR, Robitaille NM, Lupien PJ, et al. First coronary heart disease event rates in relation to major risk factors: Québec Cardiovascular Study. Can J Cardiol. 1990;6:274-280.
17. Moorjani S, Dupont A, Labrie F, et al. Increase in plasma high density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma. Metabolism. 1987;36:244-250.
18. 2 precipitation procedures for estimating cholesterol in high-density lipoproteins. Clin Chem. 1978;24:323-338.
19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
20. Laurell CB. Electroimmunoassay. Scand J Clin Lab Med. 1972;124:23-27.
21. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res. 1982;23:97-104.
22. McNamara JR, Campos H, Ordovas JM, Peterson J, Wilson PWF, Schaefer EJ. Effect of gender, age, and lipid status on low density lipoprotein subfraction distribution: results from the Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 1987;7:483-490.
23. Tchernof A, Lamarche B, Nadeau A, et al. The dense LDL phenotype: association with plasma lipoprotein levels, visceral obesity and hyperinsulinemia in men. Diabetes Care. 1996;19:629-637.
24. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willet WC, Krauss RM. Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260:1917-1921.
25. Campos H, Genest JJ, Blijlevens E, et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb Vasc Biol. 1992; 12:187-195.
26. Coresh J, Kwiterovich PO, Smith HH, Bachorik PS. Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women. J Lipid Res. 1993;34:1687-1697.
27. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 1996;276:875-881.
28. Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276:882-888.
29. de Graaf J, Hak Lemmers HL, Hectors MP, Demacker PNM, Hendriks JC, Stalenhoef AF. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb Vasc Biol. 1991;11: 298-306.
30. Nigon F, Lesnik P, Rouis M, Chapman MJ. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res. 1991;32:1741-1753.
31. Hodis HN, Mack WJ, Azen SP, et al. Triglyceride-and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation. 1994;90:42-49.
32. Davignon J, Cohn JS. Triglycerides: a risk factor for coronary heart disease. Atherosclerosis. 1996;124(suppl):S57-S64.
33. Sniderman AD, Cianflone K. Measurement of apoproteins: time to improve the diagnosis and treatment of the atherogenic dyslipoproteinemias. Clin Chem. 1996;42:489-491.
34. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1495-1507.
35. Yarnell JWG, Sweetnam PM, Marks V, Teale JD, Bolton CH. Insulin in ischaemic heart disease: are associations explained by triglyceride concentrations? the Caerphilly Prospective Study. Br Heart J. 1994;71:293-296.
36. Pyörälä K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care. 1979;2:131-141.
37. Eschwège E, Richard JL,Thibult N, et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels: the Paris prospective study, ten years later. Horm Metab Res. 1985;15:41-46.
38. Perry IJ, Wannamethee SG, Whincup PH, et al. Serum insulin and incident coronary heart disease in middle-aged British men. Am J Epidemiol. 1996; 144:224-234.
39. Haffner SM, Mykkänen L, Stern MP, Valdez RA, Heisserman JA, Bowsher RR. Relationship of proinsulin and insulin to cardiovascular risk factors in nondiabetic subjects. Diabetes. 1993;42:1297-1302.
40. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia. 1991;34:457-462.
41. McNamara JR, Jenner JL, Li Z, Wilson PW, Schaefer EJ. Change in LDL particle size is associated with change in plasma triglyceride concentration. Arterioscler Thromb Vasc Biol. 1992;12:1284-1290.
42. Yuan JN, Tsai MY, Hunninghake DB. Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy. Atherosclerosis. 1994;110:1-11.
43. Guerin M, Bruckert E, Dolphin PJ, Turpin G, Chapman MJ. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 1996;16:763-772.
44. Williams PT, Krauss RM, Vranizan KM, Wood PD. Changes in lipoprotein subfractions during diet-induced and exercise-induced weight loss in moderately overweight men. Circulation. 1990;81:1293-1304.
45. Després JP, Lamarche B. Effects of diet and physical activity on adiposity and body fat distribution: implications for the prevention of cardiovascular disease. Nutr Res Rev. 1993;6:137-159.